Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.0B
89M shares
52-week range
$7.36 – $13.90
65% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
P/S (TTM)
13.3
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
www.kuraoncology.comNo one on the platform currently holds KURA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,582,568 | $12.9M |
No one on the platform has traded KURA yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 25.2% | |||||
| Profit Margin % | -412.9% | |||||
| Free Cash Flow Margin % | -104.8% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $97M | +13.1% | $-3.22 | $-3.45–$-2.95 | — | 9 |
| 2027 | $212M | +119.7% | $-2.37 | $-3.21–$-1.56 | — | 9 |
| 2028 | $292M | +37.4% | $-1.87 | $-2.94–$-0.12 | — | 11 |
| 2029 | $493M | +69.2% | $-0.23 | $-0.53–$-0.13 | — | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $-0.88 | $-0.77 | +12.2% |
| 2026-05-12 | $-0.88 | $-0.83 | +5.7% |
| 2026-03-05 | $-0.72 | $-0.92 | -27.8% |
| 2025-11-04 | $-0.57 | $-0.85 | -49.1% |
| 2025-08-07 | $0.15 | $-0.75 | -600.0% |
| 2025-05-01 | $-0.51 | $-0.66 | -29.4% |
| 2025-02-26 | $-0.65 | $-0.22 | +66.2% |
| 2024-11-07 | $-0.64 |
| $-0.63 |
| +1.6% |
| -1.26% |
| $567M |
| — |
| PROKProKidney Corp. | $1.81 | +0.00% | $609M | — |
| REPLReplimune Group, Inc. | $12.99 | -0.92% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SNDX Sorry to go on a long diatribe-and many here won't understand where I'm coming from. But IMO the debt deal $SNDX did was a very bad call. Having watched it trade-You can clearly see how the stocks trading changed once conversations started w bankers around the deal. How it's correlation to XBI stopped- how the short position dropped 5mm shares on 5/31 reflected the deal closing and then capping stock near exercise price. IMO $SNDX should not have taken GIA strategy. Look to @Night_Owl_Biotech previous posts to further understand. They should have pursued acquisition; but mgmt. preferred being granted RSU's-salary etc. and issued debt to pursue buildout. Were they just naive w debt deal and what comes with it? Trusting the underwriters? Or they didn't care? Trimmed a bunch higher and will buy back if there is a reason-like revenue numbers backing up the talk. Meanwhile $KURA CEO actively buying $2.5M stock in the open market-with more to come Plz. bring on the criticism.. Thx.
View on StockTwits ↗
$KURA Chart pattern and Technical analysis time! (YAY!) We have a megaphone chart pattern that generally gives zero fucks about the MA's except for earlier this year in May when it showed the 50 some respect. Only hope at this point is an oversold stochastic + 50MA could get this stock accumulating again, but who really knows? Yeah, we're also at the 50% Fib, but that doesn't prove the stock is going to turn around. Let's see what happens tomorrow, but if I had to make a prediction, we have a 1-3 day rebound and then continue further down the rabbit hole toward 10.
View on StockTwits ↗
● $KURA — Kura launches Caspian Therapeutics with a $50M Series A, transfers KO-7246 and related cardiometabolic assets, retains ~49.2% ownership post-financing, and sets a Sep. 29 EASD preclinical catalyst. Updated https://www.merlintrader.com/kura-oncology-inc/
View on StockTwits ↗$KURA Must read article if you are heavily invested here and feeling your weekend is coming and your mind is not on hugging you kids / grandkids/ dog or yourself but on your accounts. Investors in this particular ticker remind me of my $BAND and $ARWR and $MRNABETS just to name a few. investing in small biotech requires the need and desire to embrace uncomfortable situations. The feelings of torture, dismay and depression are all positive signs in today’s algo trading world. We have seen it time and time again but we have poor short term memories and forget the lessons. Enjoy and desire the need to bend over and get jacked in the a$shole. It means goodness is around the corner. 😌 btw. No margin please 🙏. Makes the above very difficult to see play out.
View on StockTwits ↗
$KURA The $50 million dollar crew is playing with this one. Quick Swings until momentum changes.
View on StockTwits ↗
$KURA something fishy with ST again. Never showing this hitting $12.60 and current at $12.08 with AH vol of 69k. Can't anything just be legit? Does everything in todays world have to have an agenda? Geeezzzz can't even trust a simple site like ST. Before you know it we'll be able to buy meds thru them.
View on StockTwits ↗$KURA Looking back, $12.03+ will be seen as an incredible gift. Going Long and will Swing with additional shares.
View on StockTwits ↗
@AdiDasRom $KURA, not only has the CEO recently bought $2M in stock, he also recently modified his employment agreement for an optimized payout and acceleration of option vesting if the company is aquired! Top three executives, CEO, COO, and CBO all got similar modifications.
View on StockTwits ↗
$KURA Nothing is accidental. Did you think Mr. Troy bought $2 million worth of stock for nothing? Who has ears to hear and eyes to see.
View on StockTwits ↗$KURA has taken an asset to which the market assigned very little value, attracted ~$46M of capital from sophisticated biotech/diabetes investors, retaining half of the upside, shifted development spending to Caspian, and Kura will be paid for the R&D work it was previously funding itself. A prime example of a very succesful CEO that knows what he is doing !
View on StockTwits ↗
$KURA I provided some information on the Caspian spinoff posted earlier Without adding a single dollar of debt or diluting KURA shareholders, management just attached a high-upside option to the stock. The core oncology business sets the floor, while Caspian creates an asymmetric ceiling that could add double-digit dollars to KURA's share price if the diabetes biology translates in human trials. It really is a brilliant structural play by Kura’s management team. From a valuation and risk-reward standpoint, this spin-out effectively gives KURA equity holders a free, non-dilutive call option on one of the biggest market opportunities in biopharma.
View on StockTwits ↗
$KURA https://www.pharmexec.com/view/kura-oncology-spins-out-caspian-therapeutics-50-million-test-menin-inhibition-as-a-disease-modifying-approach-diabetes
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.